| Literature DB >> 31292092 |
Ziyi Yang1, Lin Kang2, Yan Wang1, Jiaqing Xiang1, Qianying Wu1, Cong Xu1, Yanqing Zhou1, Shaoyuan Chen3, Hongcheng Fang4, Jie Liu1, Ming Dong5.
Abstract
Inflammation is closely related to the pathogenesis and prognosis of cardiovascular disease (CVD). Interleukin-37 (IL-37), an anti-inflammatory IL-1 family cytokine, shifts cytokine expression from pro- to anti-inflammation via regulation of macrophage polarization and lipid metabolism. In macrophages, IL-37 functions through both intracellular and extracellular pathways to regulate the activity of NF-kB and PTEN as well as the expression of cytokines, including IL-1β, IL-6, and IL-10. Moreover, IL-37 levels are increased in the serum of patients with heart failure, atherosclerosis, and acute coronary syndrome with no evidence of anti-inflammatory effects. However, transgenic overexpression of IL-37 improves cardiac infarct and attenuates atherosclerosis plaque expansion. Hence, it is worthwhile to investigate the precise mechanism and role of IL-37 in the pathogenesis of CVD, which may provide deeper understanding of the inflammatory response in this context. This review summarizes the regulatory role of IL-37 in systematic inflammation induced by CVD and highlights recent advancements in the clinical application of IL-37 as a therapeutic agent or biomarker for diagnosis of CVD.Entities:
Year: 2019 PMID: 31292092 DOI: 10.1016/j.cjca.2019.04.007
Source DB: PubMed Journal: Can J Cardiol ISSN: 0828-282X Impact factor: 5.223